Zevra Therapeutics (ZVRA) Operating Income Growth (3y) (2017 - 2026)

Zevra Therapeutics (ZVRA) Operating Income Growth (3y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 16.96%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.78%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -12.10%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Zevra Therapeutics 570.04 Mn 369.43 Mn 34.32 Mn 82.36%

Historic Data

Download Data
DateValue
Mar 31, 2026 82.36%
Dec 31, 2025 44.23%
Sep 30, 2025 37.95%
Jun 30, 2025 -42.08%
Dec 31, 2024 -75.70%
Sep 30, 2024 -130.77%
Jun 30, 2024 -82.51%
Mar 31, 2024 -70.35%
Dec 31, 2023 -67.70%
Sep 30, 2023 -133.10%
Jun 30, 2023 -64.00%
Mar 31, 2023 -50.35%
Dec 31, 2022 -28.30%
Sep 30, 2022 -59.38%
Jun 30, 2022 -47.03%
Dec 31, 2021 32.57%
Sep 30, 2021 50.17%
Jun 30, 2021 34.25%
Mar 31, 2021 35.20%
Dec 31, 2020 26.67%